Showing results (371-380 of 547) with videos related to
Sort By:
Pageof 55
ISME Communications|May 24, 2023
The Pathfinder plasmid toolkit for genetically engineering newly isolated bacteria enables the study of Drosophila-colonizing OrbaceaeKatherine M Elston, Laila E Phillips, Sean P Leonard, et al.Surgery|February 14, 2026
Development and implementation of an innovative mentoring committee for early-career faculty membersSamantha P Leonard, Philip N Redlich, Tracy S Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinibZibo Song, Pin Lu, Richard R Furman, et al.Revue Medicale De Liege|March 30, 2018
[Multidisciplinary management of alveolar echinococcosis : Echino-Liege Working Group]A Cambier, J B Giot, P Leonard, et al.Leukemia & Lymphoma|March 9, 2019
Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphomaSrinivasa N Gopalsamy, Kristen M Rosenthal, Amy A Ayers, et al.Chemical Communications (Cambridge, England)|November 30, 2018
A ZnCl2 water-in-salt electrolyte for a reversible Zn metal anodeChong Zhang, John Holoubek, Xianyong Wu, et al.Pharmaceutical Research|June 28, 2000
Synthetic glycopeptide-based delivery systems for systemic gene targeting to hepatocytesK Anwer, M Logan, F Tagliaferri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2026
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT TrialJohn P Leonard, Marek Trněný, Huilai Zhang, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 24, 1999
Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cellsD K Thibodeaux, S E Hunter, K E Waldburger, et al.Cancer|August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.Pageof 55